Cytosorbents (CTSO)
(Delayed Data from NSDQ)
$0.81 USD
-0.01 (-1.55%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $0.81 0.00 (0.12%) 5:36 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Cytosorbents Corporation falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 36 | 35 | 43 | 41 | 25 |
Cost Of Goods | 14 | 14 | 11 | 11 | 7 |
Gross Profit | 22 | 21 | 32 | 30 | 18 |
Selling & Adminstrative & Depr. & Amort Expenses | 54 | 52 | 55 | 40 | 37 |
Income After Depreciation & Amortization | -31 | -32 | -23 | -10 | -19 |
Non-Operating Income | 2 | -2 | -3 | 1 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -29 | -34 | -25 | -9 | -20 |
Income Taxes | -1 | -1 | -1 | -1 | -1 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -29 | -33 | -25 | -8 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -29 | -33 | -25 | -8 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -29 | -30 | -22 | -9 | -18 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -31 | -32 | -23 | -10 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.66 | 43.57 | 43.36 | 38.82 | 32.26 |
Diluted EPS Before Non-Recurring Items | -0.64 | -0.75 | -0.57 | -0.20 | -0.60 |
Diluted Net EPS (GAAP) | -0.64 | -0.75 | -0.57 | -0.20 | -0.60 |
Fiscal Year end for Cytosorbents Corporation falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 8.67 | 8.81 | 9.42 | 9.45 |
Cost Of Goods | NA | 3.36 | 3.20 | 3.40 | 3.99 |
Gross Profit | NA | 5.31 | 5.61 | 6.02 | 5.46 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 14.72 | 12.96 | 12.58 | 13.34 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -9.41 | -7.35 | -6.56 | -7.88 |
Non-Operating Income | NA | 2.76 | -1.84 | 0.41 | 0.57 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -6.65 | -9.19 | -6.15 | -7.33 |
Income Taxes | NA | -0.81 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -5.83 | -9.19 | -6.15 | -7.33 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -5.83 | -9.19 | -6.15 | -7.33 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 44.66 | 44.37 | 44.02 | 43.68 |
Diluted EPS Before Non-Recurring Items | NA | -0.12 | -0.21 | -0.14 | -0.17 |
Diluted Net EPS (GAAP) | NA | -0.12 | -0.21 | -0.14 | -0.17 |